Remnant cholesterol inflammation index (RCII) as a potential biomarker for ACPA-negative rheumatoid arthritis: evidence from dual-cohort analysis and serum lipidomics.
Aug 2026· Clinical Rheumatology· 0 citations· 24 references
Medicine
TL;DR
Elevated RCII levels were significantly elevated in ACPA-negative RA, ACPA-positive RA, undifferentiated inflammatory arthritis, dermatomyositis, and systemic lupus erythematosus compared with HCs, with the highest levels observed in ACPA-negative RA.
RCII exhibited an independent and positive association with CKM risk in the US and Chinese populations, with consistent dose-response and nonlinear trends, and may be a practical and integrative biomarker for identifying individuals with an increased CKM risk.
Mengchen Zhang, Linlin Huang, Tian Zhang et al.· Anatolian journal of cardiol...· 0 citations
Higher RCII levels, both at baseline and cumulatively, are associated with an increased risk of frailty, and this biomarker may be a promising biomarker for frailty risk stratification and a potential target for early prevention in aging populations.
Qianyu Zhou, Mengting Liu, Lianke Wang et al.· Frontiers in Nutrition· 0 citations
Serum CRP levels showed a disease specific distribution across AIDs, with the highest levels in hyperinflammatory conditions such as AOSD and MAS, suggesting their potential as disease-specific biomarkers.
Qianyue Yang, Yu-Lu Zhang, Xiaomin Li et al.· Frontiers in Immunology· 0 citations
Elevated PIV is non-linearly associated with thyroid autoantibody positivity, particularly TgAb, with stronger effects observed in women and hypertensive individuals, with stronger effects observed in women and hypertensive individuals.
Yunzhi Chen, Jialin Liao, W. Feng et al.· Endocrine· 0 citations
OBJECTIVE
While residual cholesterol (RC) and high-sensitivity C-reactive protein (hs-CRP) are independent risk factors for cardiometabolic multimorbidity (CMM), their combined predictive value remains unclear. We investigated the predictive utility of the remnant cholesterol inflammation index (RCII) for CMM incidence.
METHODS
The RCII was derived from 5,870 participants in the China Health and Retirement Longitudinal Study (CHARLS) and 2,295 in the English Longitudinal Study of Ageing (ELSA), calculated as RC (mg/dL) × hs-CRP (mg/L) / 10. Longitudinal analyses in a subcohort (n = 5,966) further assessed the associations between cumulative RCII, changes in RCII and CMM incidence.
RESULTS
Each ln-unit increase in baseline RCII was associated with a 14% (CHARLS: HR 1.14, 95% CI 1.09-1.19) and 21% (ELSA: HR 1.21, 95% CI 1.10-1.34) higher CMM risk. Similarly, cumulative RCII increments raised CMM risk by 20% (CHARLS: HR 1.20, 95% CI 1.11-1.29) and 30% (ELSA: HR 1.30, 95% CI 1.11-1.51). Transition patterns analysis showed that stable high RCII levels conferred the highest CMM risk compared to stable low RCII levels. RCII demonstrated moderate independent predictive capability for CMM and outperformed RC or hs-CRP alone.
CONCLUSION
By integrating lipid and inflammatory pathways, the RCII was significantly associated with incident CMM and may enhance early risk stratification.
Song Wen, Zhonghua Sun, Yanjun Song et al.· Diabetes Research and Clinic...· 0 citations
Findings support RCII as a complementary lipid-inflammatory residual-risk marker; however, external validation and decision-utility studies are needed before clinical implementation.
Lerui Wang, Si-Yuan Wen, Zhiyi Ma et al.· BMC Cardiovascular Disorders· 0 citations
